1-(5-Chloro-2-methylphenyl)-3-ethyl-2-thioxo-4,5-imidazolidinedione | 548796-92-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 1-(5-Chloro-2-methylphenyl)-3-ethyl-2-thioxo-4,5-imidazolidinedione
• 英文别名: 1-(5-chloro-2-methylphenyl)-3-ethyl-2-sulfanylideneimidazolidine-4,5-dione
• CAS: 548796-92-5
• 化学式: C₁₂H₁₁ClN₂O₂S
• 分子量: 282.751
• InChiKey: LTTGSHXOUXAZPK-UHFFFAOYSA-N

物化性质

• 熔点：
  173-174 °C
• 沸点：
  384.0±52.0 °C(Predicted)
• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  72.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-氯-2-甲基异硫氰酸苯酯 以 氯仿 、 水 为溶剂， 反应 21.0h， 生成 1-(5-Chloro-2-methylphenyl)-3-ethyl-2-thioxo-4,5-imidazolidinedione
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Thio-Containing Compounds with Serum HDL-Cholesterol-Elevating Properties

  摘要：

  A novel series of substituted sulfanyldihydroimidazolones (1) that modulates high-density lipoprotein cholesterol (HDL-C) has been reported to have HDL-elevating properties in several animal models. Concerns about the chemical and metabolic stability of I directed us to explore the structure-activity relationship (SAR) of a related series of substituted thiohydantoins (2). Expansion of the scope of the thiohydantoin series led to exploration of compounds in related thio-containing ring systems 3-7 and the N-cyanoguanidine derivative 8. Compounds were tested sequentially in three animal models to assess their HDL-C elevating efficacy and safety profiles. Further evaluation of selected compounds in a dose-response paradigm culminated in the identification of compound 2.39 as a candidate compound for advanced preclinical. studies.

  DOI：

  10.1021/jm030219z

文献信息

• 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis
  申请人：Wyeth

  公开号：US20030119889A1

  公开（公告）日：2003-06-26

  Antiatherosclerotic compounds of Formula I are provided: 1 wherein: R is lower alkyl, alkenyl, alkynyl, or —O—(CH 2 ) n —COOR′; R′ is lower alkyl; n is an integer of 1-3; Ar is phenyl, or phenyl substituted with one or more of halogen, lower alkyl, alkenyl, alkynyl, alkoxy, perfluoroalkyl, perfluoroalkoxy, or alkylthio; and pharmaceutically acceptable salts thereof.

  提供了化学式I的抗动脉粥样硬化化合物： 其中： R为较低的烷基，烯基，炔基，或—O—(CH 2 ) n —COOR′; R′为较低的烷基; n为1-3的整数; Ar为苯基，或苯基上取代一个或多个卤素，较低的烷基，烯基，炔基，烷氧基，全氟烷基，全氟烷氧基，或烷基硫基;以及 其药用可接受盐。
• 1,3-disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis
  申请人：Wyeth

  公开号：US07135492B2

  公开（公告）日：2006-11-14

  Antiatherosclerotic compounds of Formula I are provided: wherein: R is lower alkyl, alkenyl, alkynyl, or —O—(CH2)n—COOR′; R′ is lower alkyl; n is an integer of 1–3; Ar is phenyl, or phenyl substituted with one or more of halogen, lower alkyl, alkenyl, alkynyl, alkoxy, perfluoroalkyl, perfluoroalkoxy, or alkylthio; and pharmaceutically acceptable salts thereof.

  提供了公式I的抗动脉粥样硬化化合物： 其中： R是低烷基，烯基，炔基或—O—（CH2）n—COOR′; R′是低烷基; n为1-3的整数; Ar是苯基，或苯基上带有卤素，低烷基，烯基，炔基，烷氧基，全氟烷基，全氟烷氧基或烷基硫基;以及其药学上可接受的盐。
• US7135492B2
  申请人：——

  公开号：US7135492B2

  公开（公告）日：2006-11-14
• Design, Synthesis, and Biological Evaluation of Thio-Containing Compounds with Serum HDL-Cholesterol-Elevating Properties
  作者：Hassan Elokdah、Theodore S. Sulkowski、Magid Abou-Gharbia、John A. Butera、Sie-Yearl Chai、Geraldine R. McFarlane、Mar-Lee McKean、John L. Babiak、Steven J. Adelman、Elaine M. Quinet

  DOI：10.1021/jm030219z

  日期：2004.1.1

  A novel series of substituted sulfanyldihydroimidazolones (1) that modulates high-density lipoprotein cholesterol (HDL-C) has been reported to have HDL-elevating properties in several animal models. Concerns about the chemical and metabolic stability of I directed us to explore the structure-activity relationship (SAR) of a related series of substituted thiohydantoins (2). Expansion of the scope of the thiohydantoin series led to exploration of compounds in related thio-containing ring systems 3-7 and the N-cyanoguanidine derivative 8. Compounds were tested sequentially in three animal models to assess their HDL-C elevating efficacy and safety profiles. Further evaluation of selected compounds in a dose-response paradigm culminated in the identification of compound 2.39 as a candidate compound for advanced preclinical. studies.